Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
ADNOC Gas Targets Up to $4B Profit in 2026 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
(4) - EconoTimes)
BRIDGEWATER, N.J., Feb. 21, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to 47 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the February 20, 2018 commencement of their employment, the employees received options to purchase an aggregate 133,010 shares of Insmed common stock at an exercise price of $24.22 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a ten-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Investor Contact:
Blaine Davis
Vice President, Head of Investor Relations
Insmed Incorporated
(908) 947-2841
[email protected]
